New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
1,354.94
3.29
+0.24%
Follow LLY
Alert me
What it owns vs. what it owes Q3 FY2026, Sep 30, 2026
It owes $42.1B more in debt than it holds in cash and short-term investments. Debt has risen from $42.5B to $47.0B since Q4 FY25. Shareholders’ equity is 27.2% of the balance sheet. What is a balance sheet?
Owns
$82.8BLong-term assets
$60.4BOther short-term assets
$4.9BCash & short-term investments
Funded by
$40.3BShareholders’ equity
$60.8BOther liabilities
$47.0BDebt
Debt is 31.7% of the total; shareholders’ equity 27.2%.
Net debt has held near 28% of assets since Q4 FY25.
Net debt ÷ assets (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Total assets | $112.5B | $116.6B | $142.3B | $148.1B |
| Net debt (debt less cash) | $35.2B | $34.1B | $46.0B | $42.1B |
| Net debt ÷ assets (right axis) | 31.3% | 29.2% | 32.3% | 28.4% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
4,885.00 | 8,950.00 | 5,282.00 | 7,268.00 |
+8 more quarters Free account |
Receivables |
25,231.00 | 23,475.00 | 21,177.00 | 20,155.00 | |
Inventory |
18,194.00 | 16,793.00 | 14,529.00 | 13,744.00 | |
Other current assets |
91.00 | 86.00 | 214.00 | 147.00 | |
Total current assets |
65,263.00 | 64,672.00 | 54,835.00 | 55,629.00 | |
Property, Plant, Equpment (Net) |
32,188.00 | 29,286.00 | 26,540.00 | 24,675.00 | |
Long-Term Investments |
4,013.00 | 3,856.00 | 3,116.00 | 2,802.00 | |
Goodwill and Intangible Assets (Total) |
27,958.00 | 26,959.00 | 13,504.00 | 12,419.00 | |
Long Term Assets (Tax, Deferred) |
10,955.00 | 10,028.00 | 11,350.00 | 9,959.00 | |
Long-term assets (Other) |
7,695.00 | 7,482.00 | 7,231.00 | 6,992.00 | |
Total non-current assets |
82,809.00 | 77,611.00 | 61,741.00 | 56,847.00 | |
Total Assets |
148,072.00 | 142,283.00 | 116,576.00 | 112,476.00 | |
Notes Payable |
2,517.00 | — | 4,000.00 | 1,635.00 | |
Accounts Payable |
5,793.00 | 6,112.00 | 5,029.00 | 5,379.00 | |
Current Part of Debt |
— | 7,050.00 | — | 1,635.00 | |
Other current liabilities |
38,686.00 | 34,579.00 | 27,605.00 | 28,214.00 | |
Total current liabilities |
46,996.00 | 47,741.00 | 36,634.00 | 35,228.00 | |
Long Term Debt (Total) |
46,986.00 | 47,858.00 | 39,370.00 | 40,868.00 | |
Non-current Liabilities (Other) |
13,819.00 | 12,805.00 | 9,374.00 | 9,845.00 | |
Total non-current liabilities |
60,805.00 | 60,663.00 | 48,744.00 | 50,713.00 | |
Total liabilities |
107,801.00 | 108,404.00 | 85,378.00 | 85,941.00 | |
Additional Paid In Capital |
7,309.00 | 7,117.00 | 6,921.00 | 7,346.00 | |
Common Stock (Net) |
588.00 | 588.00 | 590.00 | 590.00 | |
Retained Earnings |
37,969.00 | 31,893.00 | 29,514.00 | 24,470.00 | |
Shareholders Equity (Other) |
(2,966.00) | (2,958.00) | (2,994.00) | (2,991.00) | |
Common Equity (Total) |
40,271.00 | 33,879.00 | 31,198.00 | 26,535.00 | |
Shareholders Equity (Total) |
40,271.00 | 33,879.00 | 31,198.00 | 26,535.00 | |
Shareholders Equity and Liabilities (Total) |
148,072.00 | 142,283.00 | 116,576.00 | 112,476.00 | |
Shares (Common) |
946.20 | 947.20 | 943.50 | 944.80 | |
Shareholders Equity (Tangible) |
12,313.00 | 6,920.00 | 17,694.00 | 14,116.00 | |
Net Debt |
42,101.00 | 45,958.00 | 34,088.00 | 35,235.00 | |
Total Debt |
46,986.00 | 54,908.00 | 39,370.00 | 42,503.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026